Subtotal $0.00
Shop Now
GLOW peptide is a marketing name, not a drug name, for a blend usually described as three peptides in one vial: BPC-157, TB-500 and GHK-Cu. The GLOW peptide blend is not FDA-approved, none of its three ingredients is an FDA-approved drug, and we found no published clinical trial of the combination. A related blend called KLOW adds a fourth peptide, KPV. This guide explains what each ingredient is, where each one stands with the FDA in 2026, and what “research use only” labels mean.
Peptide Labs does not sell GLOW, KLOW or any of these peptides. This article is information only, not medical advice.
Key Takeaways
- GLOW is usually described as BPC-157 + TB-500 + GHK-Cu; KLOW is the same three plus KPV.
- Neither blend is FDA-approved, and no clinical trial of either combination has been published.
- Human evidence for BPC-157, TB-500 and KPV is very limited; GHK-Cu research in people is mostly on skin creams.
- An FDA advisory committee backed BPC-157 and TB-500 for compounding in July 2026, but the FDA had not acted by late September 2026.
- BPC-157 and TB-500 are prohibited in sport under the WADA 2026 list.
What is the GLOW peptide blend?
The name GLOW is not regulated, so there is no official recipe. Sellers and online forums most often describe it as BPC-157, TB-500 and GHK-Cu, and the name leans on GHK-Cu’s reputation as a skin-care ingredient. Because these products are not standardized or reviewed by the FDA, the amount of each peptide, and whatever else a vial contains, can differ from seller to seller.
The blend is sold as a powder in a vial, not as a cream. That puts it in a completely different regulatory position from copper peptide serums and creams, which are sold as cosmetics.
What is in GLOW: the three components
| Component | What it is | Human evidence | U.S. status, September 2026 | WADA 2026 list |
|---|---|---|---|---|
| BPC-157 | Synthetic 15-amino-acid peptide based on part of a protein in gastric juice | 35 of 36 studies in a 2025 review were preclinical | Not FDA-approved | Named, class S0 |
| TB-500 | Synthetic fragment of thymosin beta-4 | FDA found no human exposure data | Not FDA-approved | Named, class S2 |
| GHK-Cu | Three-amino-acid peptide bound to copper | Mostly small topical cosmetic studies | Injectable form not FDA-approved | Not named |
BPC-157
BPC stands for body protection compound. Nearly all research has been in cells and animals: a 2025 systematic review in the HSS Journal found 36 eligible studies in musculoskeletal medicine, of which 35 were preclinical and one was clinical. See our BPC-157 profile.
TB-500
TB-500 is usually described as a seven-amino-acid section of thymosin beta-4, a protein found in most human cells. The FDA has stated that it identified no human exposure data for drug products containing this fragment. See our TB-500 profile.
GHK-Cu
GHK-Cu occurs naturally in human blood and is widely used in skin creams as copper tripeptide-1. Its human studies are mostly small cosmetic trials of creams, which say nothing about a peptide given by needle. See our GHK-Cu profile.
KLOW vs GLOW peptide: what is the difference?
KLOW is usually described as GLOW plus KPV, a three-amino-acid peptide (lysine, proline and valine) that matches the end of alpha-melanocyte-stimulating hormone. KPV has been studied almost entirely in cells and animals, and the FDA has said it has not identified any human exposure data for drug products containing KPV by any route. See our KPV profile and KLOW blend profile.
| GLOW | KLOW | |
|---|---|---|
| Usual description | BPC-157 + TB-500 + GHK-Cu | BPC-157 + TB-500 + GHK-Cu + KPV |
| FDA-approved | No | No |
| Clinical trials of the blend | None published | None published |
| Ingredients named on WADA 2026 list | BPC-157, TB-500 | BPC-157, TB-500 |
Has the GLOW blend been studied?
Not as a blend. Each ingredient has been studied on its own, mostly in laboratories and animals, and we found no published trial of the three together. That means there is no data on whether the peptides stay stable when mixed, how they behave together in the body or what side effects the combination might cause. Results in animals often fail to carry over to people, which is why the FDA requires controlled clinical trials before approving any drug.
Regulatory status of each GLOW component in 2026
The FDA has not approved GLOW, KLOW or any of their ingredients. The peptides are at different points in the FDA’s review of substances that pharmacies might use for compounding:
- April 15, 2026: the FDA removed 12 peptides, including BPC-157, TB-500, injectable GHK-Cu and KPV, from Category 2, its list of bulk substances with significant safety concerns, after their nominations were withdrawn. The FDA said removal does not make them eligible for compounding.
- May 14, 2026: the FDA’s updated list put non-injectable GHK-Cu back in Category 1, substances under evaluation.
- July 23-24, 2026: the FDA’s Pharmacy Compounding Advisory Committee recommended six peptides for the 503A Bulks List, including BPC-157 (by an 8-6 vote with 1 abstention), TB-500 and KPV. FDA staff had recommended against them. The votes are advisory only.
- Late September 2026: the FDA had not added any of these peptides to the 503A Bulks List.
- Before the end of February 2027: the committee is due to consider GHK-Cu.
Two points matter for blends. The committee reviewed each peptide separately, not any combination. And even if the FDA adds a peptide to the list, that would only let pharmacies compound it with a prescription; it would not make it an FDA-approved drug. For the wider legal picture, read are peptides legal?
What the FDA has said about safety
In its safety summaries, the FDA said compounded BPC-157 may carry a risk of immunogenicity (an unwanted immune response) and problems with peptide-related impurities, and that the agency lacks enough information to know whether it would cause harm in people. For TB-500 and injectable GHK-Cu it cited possible aggregation (clumping) and impurities, and for TB-500 and KPV it said it had not identified any human exposure data. Without human studies, side effects and long-term risks are unknown.
What "research use only" labels mean
Blends like GLOW are often sold as “research use only” or “not for human consumption.” The FDA looks at the whole picture, not just the label. In warning letters dated March 31, 2026 and August 24, 2026, it told online sellers of research-labeled GLP-1 peptides that evidence on their websites showed the products were intended for people, making them unapproved new drugs. Earlier FDA warning letters described BPC-157 products the same way. For the buyer, the practical problem is simple: no regulator has checked what is in the vial, how much of it or whether it is sterile.
GLOW peptides and sport
The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 under class S0 (non-approved substances) and thymosin beta-4 derivatives such as TB-500 under class S2. Both are prohibited at all times, in and out of competition. GHK-Cu and KPV are not named, but athletes should confirm any substance with their anti-doping organization, and a blend containing BPC-157 or TB-500 carries their status.
Frequently Asked Questions
What is the GLOW peptide?
GLOW is a marketing name for a peptide blend usually described as BPC-157, TB-500 and GHK-Cu. It is not an FDA-approved product, and its contents are not standardized.
What is the difference between KLOW and GLOW?
KLOW is usually described as the GLOW blend plus KPV, a short peptide from the end of alpha-melanocyte-stimulating hormone. Neither blend is FDA-approved or has been tested in a published clinical trial.
Is the GLOW peptide blend FDA-approved?
No. The FDA has not approved the blend or any of its three ingredients as a drug.
Can a pharmacy compound GLOW?
As of late September 2026, none of the three peptides was on the FDA’s 503A Bulks List. An advisory committee recommended BPC-157 and TB-500 in July 2026, but the vote is non-binding and covered single peptides, not blends.
Is GLOW banned in sport?
BPC-157 and TB-500 are named on the WADA 2026 Prohibited List and are banned at all times, so a blend containing them is prohibited for athletes subject to WADA rules.
Does Peptide Labs sell GLOW or KLOW?
No. Peptide Labs does not sell GLOW, KLOW, BPC-157, TB-500, GHK-Cu or KPV in any form.
Peptide Labs does not sell these compounds. This page is general information, not medical advice, and nothing here is an offer or a guide to use. If you have questions about peptides or a related health concern, talk to a licensed healthcare provider who knows your medical history.
Last reviewed September 2026.
Related guides: Are Peptides Safe? Side Effects and Risks by Type of Peptide, Are Peptides Legal? How U.S. Law Treats Each Type of Peptide, Peptides for Skin: Cosmetic Peptides, Copper Peptides and What Studies Show.